MXPA99010523A - Metodos para mejorar el funcionamiento del tractogastrointestinal superior. - Google Patents

Metodos para mejorar el funcionamiento del tractogastrointestinal superior.

Info

Publication number
MXPA99010523A
MXPA99010523A MXPA99010523A MX9910523A MXPA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX 9910523 A MX9910523 A MX 9910523A MX PA99010523 A MXPA99010523 A MX PA99010523A
Authority
MX
Mexico
Prior art keywords
upper gastrointestinal
methods
glp
gastrointestinal tract
tissue
Prior art date
Application number
MXPA99010523A
Other languages
English (en)
Spanish (es)
Inventor
J Drucker Daniel
Original Assignee
Ontario Inc 1149336
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en
Priority claimed from US09/059,504 external-priority patent/US6051557A/en
Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336
Publication of MXPA99010523A publication Critical patent/MXPA99010523A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MXPA99010523A 1997-05-16 1998-05-15 Metodos para mejorar el funcionamiento del tractogastrointestinal superior. MXPA99010523A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4675497P 1997-05-16 1997-05-16
GBGB9715481.9A GB9715481D0 (en) 1997-07-23 1997-07-23 Methods of enhancing functioning of the upper gastrointestinal tract
US09/059,504 US6051557A (en) 1997-05-16 1998-04-13 Methods of enhancing functioning of the upper gastrointestinal tract
PCT/CA1998/000497 WO1998052600A1 (en) 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract

Publications (1)

Publication Number Publication Date
MXPA99010523A true MXPA99010523A (es) 2004-09-01

Family

ID=27268946

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99010523A MXPA99010523A (es) 1997-05-16 1998-05-15 Metodos para mejorar el funcionamiento del tractogastrointestinal superior.

Country Status (13)

Country Link
EP (1) EP0981362B1 (https=)
JP (2) JP4699576B2 (https=)
CN (1) CN1264307B (https=)
AT (1) ATE253375T1 (https=)
AU (1) AU746633B2 (https=)
BR (1) BR9808804A (https=)
CA (1) CA2289652C (https=)
DE (1) DE69819488T2 (https=)
DK (1) DK0981362T3 (https=)
ES (1) ES2210756T3 (https=)
MX (1) MXPA99010523A (https=)
PT (1) PT981362E (https=)
WO (1) WO1998052600A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0981362T3 (da) * 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
RU2164349C1 (ru) * 1999-07-27 2001-03-20 Нижегородская государственная медицинская академия Способ определения стоматологического статуса
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ES2310192T3 (es) * 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
ES2427150T3 (es) 2004-11-01 2013-10-29 Nps Pharmaceuticals, Inc. Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
ES2555164T3 (es) * 2010-08-30 2015-12-29 Nps Pharmaceuticals, Inc. Síntesis de fase sólida de h[Gly2]GLP-2
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
EP3299023A4 (en) * 2015-05-21 2019-03-20 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences OXYGEN ARM-TREATED MESENCHYMM STEM CELL AND ITS USE
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
CN108273038B (zh) * 2018-03-16 2019-03-19 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN110226566A (zh) * 2019-07-12 2019-09-13 南京中医药大学 一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE60142885D1 (de) * 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
EP1012186B1 (en) * 1996-12-06 2002-07-17 Amgen Inc., Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
DK0981362T3 (da) * 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal

Also Published As

Publication number Publication date
DK0981362T3 (da) 2004-03-15
EP0981362B1 (en) 2003-11-05
ES2210756T3 (es) 2004-07-01
PT981362E (pt) 2004-03-31
AU7516398A (en) 1998-12-11
WO1998052600A9 (en) 2000-03-09
DE69819488D1 (de) 2003-12-11
DE69819488T2 (de) 2004-08-26
WO1998052600A1 (en) 1998-11-26
CA2289652C (en) 2012-02-28
CN1264307A (zh) 2000-08-23
CN1264307B (zh) 2013-10-30
JP4699576B2 (ja) 2011-06-15
HK1030160A1 (en) 2001-04-27
AU746633B2 (en) 2002-05-02
JP2009280598A (ja) 2009-12-03
EP0981362A1 (en) 2000-03-01
BR9808804A (pt) 2001-09-18
JP2002502369A (ja) 2002-01-22
CA2289652A1 (en) 1998-11-26
ATE253375T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
MXPA99010523A (es) Metodos para mejorar el funcionamiento del tractogastrointestinal superior.
ATE233096T1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
Layer et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption
Nishi et al. The soybean β-conglycinin β 51–63 fragment suppresses appetite by stimulating cholecystokinin release in rats
Wormsley Response to duodenal acidification in man: III. Comparison with the effects of secretin and pancreozymin
MXPA05002991A (es) Analogos de ghrh.
Morley The aging gut: physiology
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
CA2246733A1 (en) Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK0810829T3 (da) Aminosyresammensætninger og anvendelse deraf til klinisk ernæring
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE259829T1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
EP0797999A3 (en) Formulations of obesity protein
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
Melvin et al. The gut as an endocrine organ: role in the regulation of food intake and body weight
Pereira et al. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome
ATE425763T1 (de) Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
Kamakura et al. Colonic delivery of nutrients for sustained and prolonged release of gut peptides: a novel strategy for appetite management
Myojo et al. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro
JP2013501736A (ja) 神経変性の修復方法
EP1455766A4 (en) Thymosin-ALPHA-1 PEPTIDE / POLYMER CONJUGATES
Betancur et al. Corticosteroid regulation of IL-1 receptors in the mouse hippocampus: effects of glucocorticoid treatment, stress, and adrenalectomy
YAMASHITA et al. Gastrointestinal hormone in dumping syndrome and reflux esophagitis after gastric surgery
Walsh et al. Localization of bombesin-like immunoreactivity (BLI) in gut and brain of rat

Legal Events

Date Code Title Description
FG Grant or registration